From €3111EUR$3,500USD£2,693GBP
- Report
- September 2024
- 82 Pages
Japan
From €3111EUR$3,500USD£2,693GBP
- Report
- July 2024
- 190 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- July 2024
- 181 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- July 2024
- 189 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- July 2024
- 182 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- June 2024
- 183 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- June 2024
- 180 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- May 2024
- 185 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- May 2024
- 182 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- May 2024
- 182 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- May 2024
- 182 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- May 2024
- 185 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- April 2024
- 185 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- April 2024
- 180 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- April 2024
- 183 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- April 2024
- 180 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- February 2024
- 175 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- February 2024
- 172 Pages
Global
From €3999EUR$4,500USD£3,463GBP
- Report
- November 2023
- 178 Pages
Global
From €3999EUR$4,500USD£3,463GBP

The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more